AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03255122 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: I-CALM
Description: Families receiving I-CALM will immediately receive a videoconferencing-based, Internet-delivered format of an evidence-based CBT treatment for early child social anxiety disorder (Coaching Approach behavior and Leading by Modeling, or the CALM Program; Puliafico, Comer, \& Albano, 2013) in which therapists and families meet in real-time via videoconferencing and parent-child interactions are broadcast from the family's home via a webcam while therapists provide bug-in-the-ear coaching from a remote site. Parents are taught and guided in how to coach their young anxious child to engage in brave, approach behavior.
Study NCT03255122 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Delayed I-CALM
Description: Families receiving Delayed I-CALM will participate in a waitlist period, and then will complete the I-CALM treatment program.
Study NCT00406250 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: intravitreal injection
Description: 1.25 mg in 0.05 cc of bevacizumab
Study NCT00406250 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: intravitreal injection
Description: 1.25 mg of bevacizumab intravitreally injected in a steril field
Study NCT03635281 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Recruitment manoeuvers
Description: Recruitment manoeuvers will be performed as follow Recruitment manoeuvers~1. set FIO2 at 1.0~2. Ppeak limit at 45 cmH2O~3. Respiratory rate set at 6~4. I:E set at 1:1~5. Raise the VT at step of 2 ml/kg PBW until the Pplat is between 30-40 cmH2O~6. If the maximum VT is set without rasing the Pplat, raise PEEP~7. Allow three respiratory cycles with Pplat between 30 and 40 cmH2O~8. End of RM~The recruitment manouvers will be performed after 20 minutes of OLV. At the end of the RM, the VT will be set back to 5 ml/kg while the PEEP will be chosen according to the best static compliance with a decremental trial (from 16 cmH2O, lowering PEEP with steps of 2 cmH2O each until the best compliance is reached).
Study NCT03635281 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: incremental PEEP
Description: In this group the a PEEP level will be added after 20 minutes from OLV. PEEP values will be chosen according to the best static compliance with an incremental trial (i.e. starting from ZEEP, the PEEP values will be increased in step of 2 cmH2O each until the best compliance is reached
Study NCT03536208 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Warfarin
Description: 5 different doses of warfarin will be assigned, ranging from 1mg to 5 mg.
Study NCT02491684 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interferon beta-1a Nebuliser solution 48 μg/mL
Description: Interferon beta-1a, 0,5 ml (24 μg, metered dose) once daily inhalation for 14 days
Study NCT02491684 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo solution for once daily inhalation for 14 days
Study NCT03184688 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: platelet rich plasma
Description: Ultrasound-guided PRP injection between proximal carpal tunnel and median nerve.
Study NCT03184688 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: Ultrasound-guided normal saline injection between proximal carpal tunnel and median nerve.
Study NCT01826019 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intervention
Description: In intervention communities, management plans will be developed by the NPHW for all enrolled participants. The NPHWs will educate participants about CVD, HT treatment, lifestyle modifications and initiate therapy according to the modified WHO CVD risk-management algorithm, including referral of high-risk patients to physicians and safety monitoring where appropriate. Participants in intervention communities will have support from family or friends (treatment supporters) and will receive educational materials and treatment reminders using text-messaging, email, and printed materials, as appropriate for the participant and the community setting. Evidence-based CV medications will be made available to the NPHWs and supervising physicians for participant treatment.
Study NCT01826019 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Usual Care
Description: At initial screening, eligible participants will be provided with a brief information booklet/leaflet (customized to the community or region) regarding lifestyle modification and be advised to see their usual physician for care that is considered appropriate. No structured interventions will be employed.
Study NCT04495023 — intervention group
Intervention type: PROCEDURE
Intervention: Left elective colectomy
Description: Open or laparoscopic left elective colectomy with colo-rectal anastomosis
Study NCT01350947 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-Azacitidine
Description: Administered on Days 1-7 of each Cycle.~Subcutaneous administration:~To provide a homogeneous suspension, the contents of the syringe must be re-suspended by inverting the syringe 2-3 times and vigorously rolling the syringe between the palms for 30 seconds immediately prior to administration.~The 5-azacitidine suspension is administered subcutaneously.~Intravenous Administration:~5-Azacitidine solution is administered intravenously. Administer the total dose over a period of 10-40 minutes.
Study NCT01188343 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Japanese encephalitis chimeric virus: Measles, mumps, and rubella live attenuated virus
Description: 0.5 mL each; Subcutaneous (SC)
Study NCT01188343 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Japanese encephalitis chimeric virus: Measles, mumps, and rubella live attenuated virus
Description: 0.5 mL each, Subcutaneous (SC)
Study NCT01188343 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Japanese encephalitis chimeric virus: Measles, mumps, and rubella live attenuated virus
Description: 0.5 mL each, subcutaneous (SC)
Study NCT01380015 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High Rosmarinic Acid Spearmint Tea
Description: The investigational product will be a high rosmarinic acid spearmint tea (700B) developed by the Department of Plant Agriculture, University of Guelph. Clone 700B has been selectively bred to contain a rosmarinic acid content 15-20 times greater than that of typical mint.
Study NCT03635593 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CBD
Description: Participants will be randomized to CBD 10mg capsules for 12 weeks. Participants will start with 1, CBD (10mg) capsule per day and self-titrate up to 8, 10mg CBD capsules (80mg) per day as needed.
Study NCT03635593 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CBD+THC
Description: Participants will be randomized to CBD+THC 10mg (CBD 5mg + THC) for 12 weeks. Participants will start with 1, 10mg CBD+THC (5mg+5mg) capsule per day and self- titrate up to 8, 10mg CBD+THC (5mg+5mg) capsules to a maximum of 80mg (40mg CBD + 40mg THC) per day as needed.
Study NCT03635593 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants randomized to placebo 10mg capsules for 12 weeks. Participants will start with 1, 10mg placebo capsule per day and self-titrate up to 8 10mg placebo capsules (80mg) per day.
Study NCT01003678 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clofarabine
Description: Dose Escalation Schedule - Level 1: 1 mg daily x 5 days (orally) followed by 23 days off drug.~Levels 2, 3, 4 and 5 are: 3, 5, 10 and 15 mg daily x 5 days followed by 23 days off drug.
Study NCT04433702 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mercury™ Multi-Pressure Dial (MPD) Experimental Goggle
Description: The Mercury™ MPD applies negative pressure to one of the two goggles inducing an IOP reduction of 10 mmHg. This is randomized for each subject in the trial.~The Mercury™ MPD consists of:~1. Goggles: seal against the bony orbit with straps around head. The goggles separately enclose each eye, with each eye individually connected to a pressure-modulating pump.~2. Programmable pump: applies negative pressure inside the goggles via clear tubing attached to a handheld device
Study NCT04433702 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Mercury™ Multi-Pressure Dial (MPD) Placebo Goggle
Description: The Mercury™ MPD applies no negative pressure to one of the two goggles eliciting no IOP reduction. This is randomized for each subject in the trial.~The Mercury™ MPD consists of:~1. Goggles: seal against the bony orbit with straps around head. The goggles separately enclose each eye, with each eye individually connected to a pressure-modulating pump.~2. Programmable pump: applies negative pressure inside the goggles via clear tubing attached to a handheld device
Study NCT00665912 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Standard post-lobectomy wound care plus use of PRP and PPPc prepared by GPS and Plasmax respectively
Description: GPS is used to create the platelet rich plasma (PRP). Plasmax is used to create the concentrated platelet-poor plasma (PPPc). Both PRP and PPPc will be used for wound care in the thoracic cavity post-lobectomy.
Study NCT00665912 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard post-lobectomy wound care
Description: Standard post-lobectomy wound care
Study NCT01970722 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Given IP or IV
Study NCT01970722 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Given IP
Study NCT01970722 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine Hydrochloride
Description: Given IP or IV
Study NCT01970722 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT01970722 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Given IP or IV
Study NCT01970722 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegylated Liposomal Doxorubicin Hydrochloride
Description: Given IP or IV
Study NCT01970722 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT01970722 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Therapeutic Conventional Surgery
Description: Undergo surgery
Study NCT01861314 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Given SC
Study NCT01861314 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine
Description: Given IV
Study NCT01861314 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT01861314 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies
Study NCT01861314 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib Tosylate
Description: Given PO
Study NCT03292926 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: Bupivacaine will help treat pain and sensation after ACL repair
Study NCT03292926 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound
Description: Ultrasound will guide anesthesiologist in performing the different nerve blocks
Study NCT03292926 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Dexamethasone will be used to prolong block duration
Study NCT05683028 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Control Training
Description: Cognitive Control Training (CCT) makes use of a very basic cognitive task that strongly loads on working memory and cognitive control processes, namely the adaptive Paced Auditory Serial Addition Task (aPASAT) where participants are given a number every 3 seconds and are asked to add the number they just heard with the number they heard before. Task difficulty is modified based on the participants current task performance, allowing training of cognitive control. Participants in the intervention group will start the CCT training after completion of ECT with a maximum time interval of 7 days. Training sessions will be performed on a tablet or computer and participants will complete five sessions per week (20 minutes per session) for a period of two weeks.
Study NCT05683028 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Active Control
Description: Participants in the active control group will start placebo training after completion of ECT with a maximum time interval of 7 days. The placebo task consists of a task similar to the experimental condition but that does not train cognitive control. Prior research confirmed that this condition controls for non-specific effects of the training and motivational issues. Participants will perform the sessions on a tablet or computer and complete five sessions per week (20 minutes per session) for a period of two weeks.
Study NCT03234595 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cerebraca wafer
Description: Eligible patients will receive Cerebraca wafer implantation with adjuvant temozolomide (TMZ) for the safety and efficacy in this study. At Phase I, the MTD will be determined by DLT. At Phase IIa, up to 12 evaluable patients will be enrolled for the efficacy and safety of Cerebraca wafer implantation. At Phase IIa, the cavity surface after tumor removal will be maximally covered by Cerebraca wafer without exceeding the MTD defined at Phase I. Patients in Phase I receive treatment as designed for Phase IIa, the data will be incorporated into Phase IIa to reduce the patient number. The overall patient number in this study is therefore between 2 to 36 evaluable patients.
Study NCT04552301 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Processing Therapy
Description: Integrated CPT. CPT is based on a social cognitive theory of PTSD that focuses on how the traumatic event is construed and coped with by a person who is trying to regain a sense of mastery and control in his or her life. The asthma components that will be integrated into the intervention include psychoeducation about asthma, barriers to asthma self-care, asthma medication education, inhaler technique, and asthma self-management behaviors.
Study NCT04552301 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Psychotherapy
Description: The Study Interventionist will conduct generalized supportive psychotherapy with the participants to provide emotional support for both PTSD and general education for asthma.
Study NCT04552301 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Targeted Asthma Education
Description: The manualized 10-session program of asthma self-management
Study NCT04552301 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: General Asthma Education
Description: A 10-session program of similar time
Study NCT04762095 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: mindfulness stress reduction program
Description: mindfulness stress reduction program
Study NCT04263623 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmecamylamine HCl
Description: Investigational drug
Study NCT04263623 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral tablet containing no active drug.
Study NCT02105740 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Hypnosis
Description: The hypnosis intervention consists of two 40-minute sessions, with an interval of 7 days between them, emphasizing the pain blocking, the well-being of the patient and the reduction of the symptoms of anxiety and depression of the same.
Study NCT02105740 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: The control and experimental groups respond in 3 different moments to Visual Analogue Scale (VAS) for the evaluation of pain, and to Hospital Anxiety and Depression Scale (HADS) to evaluate depression and the anxiety. The first meeting will be made before the hypnosis. In the second meeting, within an interval of 7 days, the scales will be applied in all patients. Before applying the scales, the hypnosis group will be submitted to the session. The third meeting will occur two weeks later, where the scales will be only applied to compare the groups.
Study NCT04423666 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Walking using a wireless pedometer
Description: See arm/group
Study NCT04046367 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Prehabilitation
Description: Prehabilitation: The intervention of a physiotherapist will be added to the components of the control group. Patients will receive practical instructions on aerobic and resistance physical activity, as well as training of their inspiratory muscles.
Study NCT04046367 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Standard group intervention. Educational program and cognitive-behavioral intervention. The patient receives training in nutrition and cognitive-behavioral therapy, as well as standard instructions to increase physical activity.
Study NCT01010828 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Incision technique
Description: Tri-Vector Approach retains the majority of 3 vectors of quadriceps.
Study NCT01010828 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Incision technique
Description: Mini Mid-Vastus Approach
Study NCT03982121 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFOX regimen
Description: Oxaliplatin 85 mg/m² Leucovorin (LV) levogyre form (LLV) 200 mg/m² or dextro-levogyre (DL-LV) racemic mixture 400 mg/m²) Fluorouracil 2400 mg/m²
Study NCT03982121 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab 240 mg
Study NCT03982121 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Ipilimumab 5 or 10 or 25 mg
Study NCT03982121 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLA-SE
Description: GLA-SE 1 or 2 or 5 or 10 or 20 μg
Study NCT00551642 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nitric oxide
Description: Nitric Oxide vapour (gas) for inhalation (400 ppm)
Study NCT00551642 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo gas for inhalation
Study NCT04225195 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amphotericin B cholesteryl sulfate complex for injection(ABCD)
Description: IC patients will only receive intravenous treatment with ABCD, with the longest course of treatment up to 42 days. ABCD will be administered once a day at a dose of 3-4 mg/kg. Visit plan: screening period (D-4 to D-1), baseline period (D1), treatment period and follow-up period (14±3days after the end of the last dose of ABCD).~IA patients will be treated with ABCD for 4 weeks first, followed by oral administration of voriconazole. The total course of treatment should be at least 6 to 12 weeks. ABCD dosing regimen will be the same as that for IC patients. Visiting plan: screening period (D-4to D-1), baseline period (D1), treatment period and follow-up period.
Study NCT04351334 — intervention group
Intervention type: DRUG
Intervention: Alectinib
Description: Observational treatment based on physician choice
Study NCT01808586 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Betamethasone
Description: 6 mg/mL injected into the facet joint as dictated by modified dual-comparative medial branch block diagnostic protocol
Study NCT01808586 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: 4mg/mL
Study NCT01808586 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Intramuscular Lidocaine
Description: 2%
Study NCT01808586 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Home Exercise
Description: Standardized home exercise program
Study NCT04013997 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EksoGT
Description: The intervention group received a minimum of 15 hours of standard of care, including physical and occupational therapy, for acute inpatient rehabilitation per week. After enrolling into the study, participants received locomotor training with the exoskeleton as part of their acute inpatient rehabilitation using the Ekso. Standing and walking with the Ekso started as soon as the clinical team determined it was safe for participants to begin standing, and continued until the participant was discharged from inpatient rehabilitation.
Study NCT01547923 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Blood sample for phenotypic and pharmacogenetic analysis.
Description: Prior to treatment by 5-FU, a DPD deficiency is identified thanks to just one blood sample (lithium heparinate).
Study NCT01547923 — intervention group
Intervention type: GENETIC
Group type: OTHER
Intervention: Blood sample for phenotypic and pharmacogenetic analysis.
Description: Blood sample (lithium heparinate) will be taken prior to treatment but not analysed.
Study NCT04828681 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Cardiac magnetic resonance imaging
Description: Cardiac magnetic resonance imaging was performed 5.0 ± 5.8 days after the primary PCI. MVO, infarct size, and myocardial salvage index were quantitatively assessed in CMR.
Study NCT02512705 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pinel Restraints
Study NCT02512705 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Seclusion Room
Study NCT01751529 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Contrast-enhanced Ultrasound
Description: All patients will undergo a contrast-enhanced ultrasound prior to planned resection or ablative therapy or as part of routine screening for kidney cancer.